Dimensional Fund Advisors LP Raises Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Dimensional Fund Advisors LP raised its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 34.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,098 shares of the company’s stock after acquiring an additional 4,892 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Cardiff Oncology were worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of CRDF. Ground Swell Capital LLC bought a new stake in Cardiff Oncology in the 2nd quarter valued at $38,000. American Century Companies Inc. increased its holdings in Cardiff Oncology by 98.7% in the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after acquiring an additional 22,536 shares during the last quarter. Rhumbline Advisers bought a new stake in Cardiff Oncology in the 2nd quarter valued at $102,000. Thoroughbred Financial Services LLC bought a new stake in Cardiff Oncology in the 2nd quarter valued at $116,000. Finally, Callan Capital LLC increased its holdings in Cardiff Oncology by 37.2% in the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after acquiring an additional 11,600 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on shares of Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price target on the stock.

Cardiff Oncology Trading Up 1.5 %

Shares of NASDAQ:CRDF opened at $2.67 on Wednesday. The company has a market capitalization of $119.42 million, a price-to-earnings ratio of -2.97 and a beta of 1.96. Cardiff Oncology, Inc. has a 12 month low of $0.94 and a 12 month high of $6.42. The firm’s 50-day moving average is $2.44 and its 200 day moving average is $3.01.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same quarter in the previous year, the company posted ($0.25) earnings per share. As a group, equities analysts forecast that Cardiff Oncology, Inc. will post -1 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.